Dasatinib in breast cancer: Src-ing for response in all the wrong kinases

Src is a non-receptor tyrosine kinase that has been associated with carcinogenesis, impairs osteoclast bone resorption, enhances angiogenesis in vivo, and plays a role in the development of breast cancer bone metastases (1-3). Writing in Clinical Breast Cancer, Morris et al. present the results of a single-arm phase II clinical trial evaluating a combination of paclitaxel and dasatinib, a Src inhibitor, in patients with HER2-negative metastatic breast cancer (4).